Bedrosian; Camille

Patent Applications and Registrations

Patent applications and USPTO patent grants for Bedrosian; Camille.The latest application filed is for "methods for treatment of refractory generalized myasthenia gravis".

Company Profile

4.5.16

Bedrosian; Camille - Woodbridge CT
Bedrosian; Camille - Cheshire CT

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor Grant 11,244,744 - Bell , et al. February 8, 2	2022-02-08
Methods For Treatment Of Refractory Generalized Myasthenia Gravis App 20210246196 - Bedrosian; Camille ; et al.	2021-08-12
Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor Grant 11,031,102 - Bell , et al. June 8, 2	2021-06-08
Dosage And Administration Of Anti-c5 Antibodies For Treatment Of Protein-losing Enteropathy In Patients App 20200172603 - ADIV; Orly Eshach ; et al.	2020-06-04
Methods For Treating Complement-associated Disorders App 20200140531 - ROTHER; Russell P. ; et al.	2020-05-07
Efficacy Of An Anti-c5 Antibody In The Prevention Of Antibody Mediated Rejection In Sensitized Recipients Of A Kidney Transplant App 20200123238 - BEDROSIAN; Camille	2020-04-23
Identifying And Treating Subpopulations Of Paroxysmal Nocturnal Hemoglobinuria (pnh) Patients App 20190135903 - Bedrosian; Camille	2019-05-09
Method For Treating A Patient In Compliance With Vaccination With Eculizumab Or An Eculizumab Variant App 20180142010 - BELL; Leonard ; et al.	2018-05-24
Methods For Treating Complement-associated Disorders App 20170369562 - ROTHER; Russell P. ; et al.	2017-12-28
Methods for Treatment of Refractory Generalized Myasthenia Gravis App 20170342139 - Bedrosian; Camille ; et al.	2017-11-30
Risk Evaluation And Management Strategy Involving Patient Follow-ups Relating To The Use Or Discontinuation Of A Complement Inhibitor App 20170277835 - BELL; Leonard ; et al.	2017-09-28
Methods for treating complement-associated disorders Grant 9,771,418 - Rother , et al. September 26, 2	2017-09-26
Methods For Treating Complement-associated Disorders App 20170015740 - Rother; Russell P. ; et al.	2017-01-19
Methods For Treating Complement-associated Disorders App 20160355580 - ROTHER; Russell P. ; et al.	2016-12-08
Methods For Treating Complement-associated Disorders App 20160355579 - Rother; Russell P. ; et al.	2016-12-08
Methods And Compositions For Treating Complement-associated Disorders App 20160319004 - Rother; Russell P. ; et al.	2016-11-03
Methods and compositions for treating complement-associated disorders Grant 9,447,176 - Rother , et al. September 20, 2	2016-09-20
Method For Treating A Complement Mediated Disorder Caused By An Infectious Agent In A Patient App 20160168237 - Fontenot; Darrell ; et al.	2016-06-16
Risk Evaluation And Management Strategy Involving Patient Follow-ups Relating To The Use Or Discontinuation Of A Complement Inhibitor App 20160140298 - BELL; Leonard ; et al.	2016-05-19
Methods And Compositions For Treating Complement-associated Disorders App 20120225056 - Rother; Russell P. ; et al.	2012-09-06

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.